Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Black Diamond Therapeutics, Inc.

Market Cap 104M 90.5M 83.42M 78.17M 146M 9.99B 149M 995M 385M 4.81B 392M 383M 16.74B P/E Ratio 2026 *
-2.81x
P/E Ratio 2027 * -1.81x
Enterprise Value 104M 90.5M 83.42M 78.17M 146M 9.99B 149M 995M 385M 4.81B 392M 383M 16.74B EV / Sales 2026 *
18.8x
EV / Sales 2027 * -
Free-Float
99.38%
Yield 2026 *
-
Yield 2027 * -
1 day-1.62%
1 week-12.92%
Current month-18.02%
1 month-38.10%
3 months-19.11%
6 months-34.06%
Current year-25.10%
1 week 1.78
Extreme 1.78
2.01
1 month 1.78
Extreme 1.78
3.97
Current year 1.78
Extreme 1.78
3.97
1 year 1.78
Extreme 1.78
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
13.29
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 49 2018-11-30
Date Insider Type Main position Quantity % Market Cap.
03-19Free

Director

6,919 0.0121%
03-19
NEA Management Co. LLC
OtherCompany 0 0%
03-19Free

Director

6,105 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-12.92%-23.21%-7.61% 104M
+1.65%+6.42%+53.16%+112.78% 55.58B
+0.03%+0.33%+49.22%+43.94% 43.47B
+3.93%-0.06%-15.10%-18.04% 22.64B
+5.27%-7.82%-1.29%+388.48% 20.96B
+2.27%-6.54%+10.27%-30.61% 15.79B
+0.53%+2.08%+8.89%-39.59% 15.3B
+1.75%+1.92%+29.13%+178.65% 13.45B
+7.45%+7.68%+16.57% - 11.74B
-5.27%-0.43%+87.77%+208.02% 10.96B
Average +1.59%-1.67%+21.54%+92.89% 21B
Weighted average by Cap. +1.85%+0.76%+31.29%+98.39%

Financials

2026 *2027 *
Net sales 5.56M 4.82M 4.44M 4.16M 7.78M 532M 7.94M 53.01M 20.52M 256M 20.86M 20.41M 892M -
Net income -40.47M -35.12M -32.38M -30.34M -56.68M -3.88B -57.86M -386M -150M -1.87B -152M -149M -6.5B -70.04M -60.79M -56.03M -52.5M -98.09M -6.71B -100M -668M -259M -3.23B -263M -257M -11.24B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
26-06-11 1.820 $ -1.62% 1,446,066
26-06-10 1.850 $ -2.63% 1,549,705
26-06-09 1.900 $ +2.70% 1,719,949
26-06-08 1.850 $ -6.09% 1,114,102
26-06-05 1.970 $ -5.74% 1,022,729
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.820USD
Average target price
9.857USD
Spread / Average Target
+441.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!